Study on Bill S-209, An Act respecting Pandemic Observance Day
https://policybase.cma.ca/link/policy14467

POLICY TYPE  Parliamentary submission
DATE  2022-02-09
TOPICS  Health care and patient safety
Ethics and medical professionalism

Documents

Appearance before the Senate Standing Committee on Social Affairs, Science and Technology

Study on Bill S-209, An Act respecting Pandemic Observance Day

Dr. J.J. Wilson, M.D., F.R.C.P.C.
President of the Canadian Medical Association

February 09, 2022

[signature]

CMA Submission to the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities’ study of Bill C-3, An Act to amend the Criminal Code and the Canada Labour Code

https://policybase.cma.ca/link/policy14464

POLICY TYPE
Parliamentary submission

DATE
2021-12-15

TOPICS
Health care and patient safety
Ethics and medical professionalism

Documents
Disclosure of COVID-19 Vaccination Status by Physicians

POLICY TYPE  Policy document
DATE        2021-10-22
TOPICS      Physician practice, compensation, forms

Documents
COVID-19 Vaccine Global Intellectual Property Policy

POLICY TYPE  
Policy document

DATE  
2021-10-22

TOPICS  
Physician practice, compensation, forms

Documents
Vaccine acceptance

https://policybase.cma.ca/link/policy14450

POLICY TYPE  Policy document
DATE  2021-08-21
TOPICS  Health care and patient safety
Population health, health equity, public health

Documents

Vaccine acceptance

Policy position recommendation

1. High quality accommodation to address the needs of the parent. Public health programs need to be sensitive and effective in supporting parents and address the unique circumstances.

2. It is important to engage families with diverse populations, and to ask for their recommendations and guidance. Parental involvement and engagement in decision-making can reduce barriers to vaccine acceptance.

3. The lack of access to vaccination and education to reduce barriers can lead to vaccine hesitancy. For this reason, it is important to work with health care providers to ensure that families are aware of available resources and support systems.

4. It is important to develop strategies to support families in making informed decisions about vaccination and to address any concerns or questions they may have.

5. It is important to engage with families who may be hesitant about vaccination and to address any concerns or questions they may have.

6. It is important to engage with families who may be hesitant about vaccination and to address any concerns or questions they may have.
Return to school during COVID-19

https://policybase.cma.ca/link/policy14452

POLICY TYPE  
Policy document

DATE  
2021-08-21

TOPICS  
Health care and patient safety
Population health, health equity, public health

Documents

Return to school during COVID-19

Policy recommendation

1. The CMA recommends that
(a) communicable disease
(b) school systems should
(c) ensure that health
(d) strategies to prevent
(e) monitoring and
(f) public health
(g) health equity

2. The CMA recommends that
(a) communicable disease
(b) school systems should
(c) ensure that health
(d) strategies to prevent
(e) monitoring and
(f) public health
(g) health equity

3. The CMA recommends that
(a) communicable disease
(b) school systems should
(c) ensure that health
(d) strategies to prevent
(e) monitoring and
(f) public health
(g) health equity
Interchangeability of vaccines (vaccine mixing)

Interchangeability of vaccines (vaccine mixing)

Policy recommendation:

1. The Canadian Medical Association recommends that the interchangeability of vaccines be considered in the context of vaccine shortages and optimize the use of available vaccines.

2. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

3. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

4. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

5. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

6. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

7. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

8. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

9. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

10. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

11. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

12. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

13. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

14. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

15. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

16. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

17. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

18. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

19. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

20. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

21. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

22. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

23. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

24. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

25. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

26. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

27. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

28. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

29. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

30. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

31. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

32. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

33. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

34. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

35. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

36. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

37. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

38. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

39. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

40. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

41. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

42. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

43. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

44. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

45. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

46. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

47. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

48. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

49. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

50. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

51. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

52. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

53. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

54. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

55. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

56. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

57. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

58. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

59. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

60. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

61. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

62. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

63. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

64. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

65. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

66. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

67. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

68. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

69. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.

70. The interchangeability of vaccines should be considered in the context of vaccine shortages and optimize the use of available vaccines.
Firearms Control

https://policybase.cma.ca/link/policy14401

POLICY TYPE  Policy document
DATE  2021-07-15
REPLACES  Firearms control (Update 2001)
TOPICS  Population health, health equity, public health
Health care and patient safety

Documents
The Canadian Interdisciplinary Palliative Care Competency Framework

https://policybase.cma.ca/link/policy14439

POLICY TYPE  
Policy endorsement

DATE  
2020-12-05

TOPICS  
Health care and patient safety
Population health, health equity, public health

Documents
Committee Appearance – Justice and Human Rights: Bill C-7 – Amending the Criminal Code Regarding Medical Assistance in Dying
https://policybase.cma.ca/link/policy14374

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Parliamentary submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2020-11-05</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety</td>
</tr>
</tbody>
</table>

Documents
CMA Pre-budget Submission
https://policybase.cma.ca/link/policy14259

POLICY TYPE
Parliamentary submission

DATE
2020-08-07

TOPICS
Physician practice, compensation, forms
Health information and e-health
Health care and patient safety
Health systems, system funding and performance

Documents
Submission in Response to the Consultation on the Canada Emergency Wage Subsidy: Keeping Medical Clinic Employees on the Payroll

https://policybase.cma.ca/link/policy14258

POLICY TYPE Parliamentary submission
DATE 2020-06-05
TOPICS Physician practice, compensation, forms
Health systems, system funding and performance

Documents

Submission in Response to the Consultation on the Canada Emergency Wage Subsidy:
Keeping Medical Clinic Employees on the Payroll

June 5, 2020
CMA Statement on Racism

https://policybase.cma.ca/link/policy14245

POLICY TYPE
Policy document

DATE
2020-06-02

TOPICS
Ethics and medical professionalism
Health care and patient safety

Documents
Federal measures to recognize the significant contributions of Canada’s front-line health care workers during the COVID-19 pandemic
https://policybase.cma.ca/link/policy14247

POLICY TYPE
Parliamentary submission

DATE
2020-06-02

TOPICS
Physician practice, compensation, forms

Documents
Responding to the COVID-19 pandemic: Federal measures to recognize the significant contributions of Canada’s front-line health care workers

https://policybase.cma.ca/link/policy14211

POLICY TYPE
Parliamentary submission

DATE
2020-05-28

TOPICS
Health care and patient safety

Documents
Framework for Ethical Decision Making During the Coronavirus Pandemic
https://policybase.cma.ca/link/policy14133

POLICY TYPE  
Policy document

DATE  
2020-04-01

TOPICS  
Ethics and medical professionalism
Health care and patient safety

Documents
Protecting and supporting Canada’s health-care providers during COVID-19
https://policybase.cma.ca/link/policy14260

POLICY TYPE
Parliamentary submission

DATE
2020-03-23

TOPICS
Physician practice, compensation, forms
Health systems, system funding and performance
Health human resources

Documents
Emergency federal measures to care for and protect Canadians during the COVID-19 pandemic

https://policybase.cma.ca/link/policy14132

POLICY TYPE
Parliamentary submission

DATE
2020-03-16

TOPICS
Health care and patient safety

CMA recommendations for
EMERGENCY FEDERAL MEASURES TO CARE FOR AND PROTECT CANADIANS DURING THE COVID-19 PANDEMIC

Submitted to the Minister of Finance
March 16, 2020
Rural and remote practice issues
https://policybase.cma.ca/link/policy211

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2000-05-09

REPLACES
Promoting medicine as a career for rural high school students (Resolution BD88-03-78)

TOPICS
Physician practice, compensation, forms

Documents
The treating physician's role in helping patients return to work after an illness or injury (Update 2013)
https://policybase.cma.ca/link/policy10754

POLICY TYPE Policy document
LAST REVIEWED 2020-02-29
DATE 2013-05-25
REPLACES The physician's role in helping patients return to work after an illness or injury (Update 2010)
TOPICS Physician practice, compensation, forms